Company news
FibroBiologics, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 16, 2025
FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 15, 2025
FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions
December 10, 2025
FibroBiologics Announces Payoff of Outstanding Debt
November 26, 2025
FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 25, 2025
FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 24, 2025
FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
November 20, 2025
FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 19, 2025
FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 19, 2025
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 31, 2025
FibroBiologics to Present at Bio-Europe 2025
October 24, 2025
FibroBiologics to Present at the 2025 ThinkEquity Conference
October 14, 2025
FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa
September 23, 2025
FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies
September 12, 2025
FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment
September 11, 2025
FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies
September 10, 2025
FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
August 27, 2025
FBLG: Closes Third Tranche of $5M…
August 5, 2025
FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
July 31, 2025
FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
July 28, 2025
FibroBiologics to Present at the Advanced Wound Care Summit USA
July 11, 2025
FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank
July 9, 2025
FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10
July 7, 2025
FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing
June 16, 2025
FibroBiologics to Present at the BIO International Convention 2025
June 16, 2025
FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer
June 9, 2025
FBLG: Poster Presentation Shows Potential for Fibroblast Therapy in Psoriasis…
May 22, 2025
FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting
May 16, 2025
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025
FibroBiologics Presents at the ThymUS 2025 Meeting
April 29, 2025
FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean
April 11, 2025
FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics
April 8, 2025
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair
April 2, 2025
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update
March 31, 2025
FibroBiologics Announces 2025 Annual Meeting of Stockholders
March 27, 2025
FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting
March 21, 2025
FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics
March 4, 2025
FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic
February 27, 2025
FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates
February 4, 2025
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
December 29, 2024
FibroBiologics Announces $25 Million Financing
December 22, 2024
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
November 18, 2024
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
November 13, 2024
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 11, 2024
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
October 28, 2024
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
October 27, 2024
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
October 17, 2024
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
October 15, 2024
FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa
September 29, 2024
FibroBiologics Engages Southern Star Research as CRO in Australia
September 18, 2024
Decks
- Investor Presentation (September 2026)
Investor deck · 19 slides · September 2026
- Investor Day (December 2023)
Investor day · 33 slides · December 2023